IP Library Granted Patent US 8,084,197
Granted Patent B2
US 8,084,197 · App. 11/745,987 · Granted Dec 27, 2011

Identification of molecular sequence signatures and methods involving the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,197
App. No.
11/745,987
Granted
Dec 27, 2011
Kind
B2
Abstract

Novel means and methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes involve selecting probe sets that define reference sequences for sequence signatures and deriving useful data about the nature of the target nucleic acid molecule based on its hybridization to the probes. The methods are useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes.

Claims (23)

1. A method for determining whether a nucleic acid sample from a patient contains nucleic acid encoding a signature sequence characteristic of a pathogen said method comprising:

obtaining a nucleic acid containing sample from said patient;

providing a probe array comprising a first plurality of polynucleotide probe sets each probe set defining a different reference nucleotide sequence wherein each reference nucleotide sequence signature is between 15 and 30 bases in length and codes for a different amino acid sequence that is a signature sequence characteristic of said pathogen; and

a second plurality of polynucleotide probe sets each probe set defining a degenerate set of nucleotide sequences encoding each different amino acid sequence and wherein the probe set defining said degenerate set comprises at least 25% of the nucleotide sequences encoding said degenerate set;

hybridizing said nucleic acid sample to said probe array to generate a hybridization pattern; and

analyzing said hybridization pattern to determine if nucleic acid encoding a sequence signature characteristic of said pathogen is present in the sample.

2. The method of claim 1 , wherein the probe set defining said degenerate set of nucleotide sequences comprises at least 50% of the degenerate set of nucleotide sequences encoding each different amino acid sequence.

3. The method of claim 1 , wherein the probe set defining said degenerate set of nucleotide sequences comprises at least 75% of the degenerate set of nucleotide sequences encoding each different amino acid sequence.

4. The method of claim 1 , wherein the probe set defining said degenerate set of nucleotide sequences comprises at least 95% of the degenerate set of nucleotide sequences encoding each different amino acid sequence.

5. The method of claim 1 , wherein the pathogen is a mycobacterium.

6. A method for determining whether a sample from a human patient has a sequence from a member of a gene family characteristic of a pathogen comprising:

obtaining a sample comprising nucleic acid from said human patient;

providing a polynucleotide probe array comprising, for each of at least two different members of the gene family, a set of polynucleotide probes that define a reference nucleotide sequence from the member of the gene family;

hybridizing said sample comprising nucleic acid to said probe array to generate a hybridization pattern comprising hybridization data; and

processing the hybridization data to determine if the reference nucleotide sequence from one of the members of the gene family is present in the nucleic acid sample.

7. The method of claim 6 wherein the step of processing is performed by a programmable digital computer.

8. The method of claim 6 wherein the polynucleotide probe array further comprises, for each of the members of the gene family, a probe set defining a highly conserved region of the gene and a probe set defining a highly variable region of the gene.

9. The method of claim 6 wherein the polynucleotide probe array further comprises, for each of the members of the gene family, probe sets defining at least two highly conserved regions of the gene and probe sets defining at least two highly variable regions of the gene.

10. The method of claim 6 wherein the reference nucleotide sequence codes for an amino acid sequence and the array further comprises probe sets defining the degenerate set of nucleotide sequences encoding the amino acid sequence.

11. The method of claim 6 , wherein the reference nucleotide sequence is a highly conserved region of the gene family.

12. The method of claim 6 , wherein said reference nucleotide sequence is between 9 and 100 nucleotides in length.

13. The method of claim 6 wherein the probe array has a density of at least four hundred different polynucleotides sequences per square centimeter.

14. The method of claim 6 wherein the pathogen is a mycobacterium.

Assignments (4)
NOTICE OF RELEASE Recorded Apr 5, 2016
From: BANK OF AMERICA, N.A.
To: AFFYMETRIX, INC.
Reel/Frame 038361/0891 →
RELEASE OF SECURITY INTEREST Recorded Nov 13, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: AFFYMETRIX, INC.
Reel/Frame 037109/0132 →
SECURITY INTEREST Recorded Oct 28, 2015
From: AFFYMETRIX, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036988/0166 →
SECURITY AGREEMENT Recorded Jun 27, 2012
From: AFFYMETRIX, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 028465/0541 →